Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Webinar series: NETs as a Therapeutic Target

Thursday, October 24, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The final video in the webinar series focuses on the potential of NETs, specifically H3.1 histones, as a therapeutic target for sepsis. It emphasizes studies that investigate how manipulating NETs could help reduce the severe immune response associated with sepsis. The article encourages viewers to explore ongoing studies related to Nu.Q® NETs.
Price reaction · baseline $14.19 (2024-10-23 close) · hit pre-market · 8 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
+2.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Discussion on therapeutic potential of NETs for sepsis treatment.
  • Focus on innovative approaches to mitigate immune responses.
  • Highlighting ongoing studies and research in the field.

Full Press Release Details

NETs as a therapeutic target

In the final video of our series, we discuss how NETs, particularly H3.1 histones, might serve as a potential therapeutic target for treating sepsis. We focus on key studies that explore how blocking or manipulating NETs could mitigate the excessive immune response seen in sepsis.
Find out more about Nu.Q ® NETs and our ongoing studies here .

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What are NETs and their role in sepsis?

NETs, or neutrophil extracellular traps, are structures that can contribute to the immune response in sepsis.

How might NETs be manipulated for treatment?

The webinar discusses blocking or manipulating NETs to reduce excessive immune responses in sepsis.

What is the focus of the final webinar video?

The final video discusses the potential of H3.1 histones in NETs as a therapeutic target for sepsis.

Where can I find more information on ongoing studies?

More information on Nu.Q® NETs and ongoing studies is available through the provided links.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare NETs sepsis H3.1 histones Nu.Q therapeutic target
Last updated: Oct 24, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk